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AnxietyBackground: Early social isolation stress (SIS) is associated with the occurrence of anxiety behaviors. It seems
interaction between the nitrergic system and mitochondrial function plays a role in mediating the anxiety-like
behaviors. In this study, we aimed to investigate the anxiolytic effects of tropisetron in animal model of SIS
and we try to illustrate the possible role of nitrergic system and mitochondrial function.
Methods:We applied early social isolation paradigm to male NMRI mice. Animals treated with various doses of
tropisetron, nitric oxide agents or their combination and anxiety-like behaviors of animals were assessed using
valid behavioral tests including elevated plus maze (EPM), open-ﬁeld test (OFT) and hole-board test (HBT) in
their adulthood. Effects of housing conditions and drug treatments on the mitochondrial function were investi-
gated in the hippocampus by assessing the ATP, GSH, ROS and nitrite levels.
Results: Anxiogenic effects of early SIS were assessed in the EPM, OFT, andHBT. Also, SIS disruptedmitochondrial
function and caused oxidative stress in the hippocampus of stressed animals. Tropisetron showed an anxiolytic
effect in the stressedmice. Also, these effectsweremediated by nitrergic systemby affectingmitochondrial func-
tion and modulating the oxidative stress. L-arginine, a nitric oxide precursor, abolished the anxiolytic effects of
tropisetron in the behavioral tasks and blocked the protective effects of it against mitochondrial and oxidative
challenge.
Conclusions and general signiﬁcance:Our results demonstrated tropisetron attenuated the anxiogenic effects of SIS
by mitigation of the negative effects of nitric oxide on mitochondrial function.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Anxiety and stress disorders are commonmental illnesses with high
prevalence and comorbidity [1,2]. Experiencing aversive events in early
stages of life negatively affects the behavior and brain development and
also, is regarded as a putative risk factor for vulnerability to psychiatricative and nitrosative stress;
eld test; EPM, elevated plus
ually to this work; S Amiri, H
acology, School of Medicine,
4, Tehran, Iran.
armacology and Toxicology,
ces, P.O. Box: 45139-56184,
s.ac.ir (S.E. Mehr),disorders such as affective disorders [3,4]. A substantial body of evi-
dence indicates that applying social isolation stress (SIS) to rodents in-
duces a variety of long-lasting behavioral disturbances relevant to
stress such as anxiety-like behaviors [5,6]. In this regard, underlying
mechanisms through which SIS induces anxiety-like behaviors are not
clearly understood. Increasing lines of evidence indicate that mitochon-
drial dysfunction [7], oxidative and nitrosative stress (O&NS) also con-
tribute to pathogenesis of anxiety-like disorders [8–10]. Evidence
indicates that SIS-induced O&NS contributes to behavioral and neuro-
chemical alterations in rodents [11,12]. Under stressful conditions, mi-
tochondria generate excessive amounts of reactive oxygen species
(ROS), which correlates with glutathione (GSH) and ATP depletion,
and consequently oxidative damage [13–15]. Additionally, it has been
reported that anxiolytic drugs decrease the O&NS in stressed animals
[9]. Moreover, overproduction of nitric oxide (NO) in the stressful
conditions has been reported to induce anxiety-like behaviors [16]
that administration of aminoguanidine (speciﬁc inhibitor of inducible
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NOS) reversed the anxiety-like responses [17,18].Also, NO-induced
O&NS causes mitochondrial dysfunction and cell injury [19].
On the other hand, a number of studies have reported that impair-
ment in neurotransmitter systems (mostly serotonergic system) plays
a role in development of aggression, anxiety and fear in socially isolated
rodents [20–22]. Evidence suggests that 5-hydroxytryptamine3
(5-HT3) receptors, as ligand gated ion channels, are involved in devel-
opment and maturation of the brain mostly formation of the inhibitory
networks. Also, 5-HT3 receptors have been reported to contribute to
pathophysioliogy of anxiety and mood disorders that mice lacking
these receptors exhibit reduced anxiety-like behaviors [23]. In this re-
gard, several lines of research have demonstrated that tropisetron, a
5-HT3 antagonist, exhibits anxiolytic effects in both clinical and preclin-
ical studies [24,25]. According to our recent studies, we found that
tropisetron possesses protective properties against O&NS in pathologic
conditions. In this context, we showed that tropisetron is able to atten-
uate O&NS as well as inﬂammatory responses in animal models of
Alzheimer's disease and stroke [26,27]. In addition, recent studies
have reported the antidepressant-like properties of 5-HT3 antagonists
(including tropisetron) in both non-stressed and stressed animals
[28–30]. Considering that mitochondrial performance and O&NS were
reported as underlyingmechanisms involved in pathogenesis of anxiety
disorders, we tested the hypothesis that whether tropisetron is able to
decrease anxiogenic effects of early SIS via regulating themitochondrial
performance. In this study, we applied early SIS paradigm because it has
been suggested as a reliable and valid animal model to investigate the
negative impacts of social environment (such as chronic stress) on
neurobehavioral and neurochemical changes which similarly were
observed in psychiatric disorders in humans [31,32].
2. Materials and methods
2.1. Animals
Male NMRI mice (Pasteur Institute, Tehran, Iran), weighing 10–12 g
and in the postnatal day (PND: 21–23) were housed for 4 weeks under
two different conditions: 1) social condition (SC) and 2) isolated condi-
tion (IC). Socially conditioned animals were housed in groups (6 mice
per cage: 25 × 25 × 15 cm) while IC mice were housed individually in
Plexiglas boxes (24 × 17 × 12 cm) under standard laboratory conditions
(free access to food and water, temperature: 22 ± 2 °C, and 12-h light–
dark cycle). All procedures in this work were carried out in accordance
with the National Institutes of Health (NIH) Guide for the Care and Use
of Laboratory Animals (NIH publication #80-23) and institutional
guidelines for animal care and use (Department of Pharmacology,
School of Medicine, TUMS). Each experimental animal group consists
of 6–9 in behavioral assessments, and 3–6 in molecular evaluations.
2.2. Drugs
The following drugs were used in this study: L-arginine (L-arg, a NO
precursor), NG-nitro-L-arginine methyl ester (L-NAME, a non-selective
NOS inhibitor), aminoguanidine (AG, a selective iNOS inhibitor)
(Sigma, UK) and tropisetron (a selective 5-HT3 antagonist) (Sigma, St.
Louis, MO, USA). All drugs were dissolved in saline and were adminis-
tered intraperitoneally (i.p.) in the volume of 5-ml/kg animal weights.
Doses of drugs were chosen according to the previous studies as well
as our pilot studies (described below), we treated mice with L-arg
(30 min), AG and L-NAME (45 min) and tropisetron (60 min) prior to
behavioral or molecular experiments [17,33].
2.3. Experimental design
After 4 weeks of housing under isolation or social conditions,
animals (PND: 52) were subjected to behavioral tests. In the ﬁrst partof the experiment, effects of housing conditions on the anxiety-like be-
haviors were investigated using behavioral tests which are considered
as valid methods for assessing anxiety in rodents including open ﬁeld
test (OFT), hole board test (HBT), and elevated plus maze test (EPM)
[34–36].
In the next step, we investigated the possible effect of tropisetron as
well as NO agents in mediating the anxiety-like behaviors of animals. In
this regard, different sets of SC and IC mice were treated with different
doses of following drugs: tropisetron (1, 3, and 5 mg/kg), L-NAME
(5, 10 mg/kg), AG (20, 50 mg/kg), and L-arg (50, 100 mg/kg). Doses of
each drug were chosen according to the pilot treatments, which were
published in previous studies [31,33,37]. After administration of drugs,
SC animals and IC animals were subjected to mentioned behavioral
tasks. To exclude the possible effect of saline administration on animal
behavior, SC and IC groupswere injectedwith 5-ml/kg physiological sa-
line. In order to investigate the role of nitrergic system in mediating the
anxiolytic effect of tropisetron, subeffective doses of L-NAME and AG
co-administered with subeffective dose of tropisetron to both SC and
IC mice. Also, we co-administered subeffective dose of L-arg with effec-
tive dose of tropisetron. In the next step, we investigated the effects of
different housing conditions and drug treatments on the hippocampal
levels of glutathione (GSH), nitrite, and ATP and ROS production in the
different sets of animals.
2.4. Behavioral tests
2.4.1. Open-ﬁeld test (OFT)
The OFT was used to evaluate the anxiety-like behaviors of mice
in response to various treatments and housing conditions [38]. The
OFT apparatus was made of white opaque Plexiglas (50 cm ×
50 cm × 30 cm) which was dimly illuminated. Mice were placed indi-
vidually on the central zone of OFT box (30 cm × 30 cm) and spent
time in the central area was recorded by a camera for a 5 min period.
The apparatus was cleaned with 70% ethanol after testing each mouse.
2.4.2. Elevated plus maze (EPM)
The elevated plusmaze (EPM) is an appropriate test to assess the ef-
fects of both anxiogenic and anxiolytic agents in rodents [36]. The appa-
ratus was made of black opaque Plexiglas and consisted of two open
(30 × 5 cm) and closed (30 × 5 × 15 cm) arms, which were connected
by a platform area (5 × 5 cm). Testing roomwas dimly illuminated and
animals were individually placed in the center of the EPM facing to
closed arm and each behavioral session was videotaped for a 5 min pe-
riod. The apparatus was cleaned with 70% ethanol after testing each
mouse. The total time spent in the open arms, and number of entries
into the open arms were recorded over a period of 5 min and reported
as percentages.
2.4.3. Hole-board test (HBT)
Hole-board test is a reliable test to determine the anxiogenic/anxio-
lytic state in mice [38]. The apparatus was made of a white Plexiglas
square (50 cm × 50 cm) with 16 equally sized holes (3 cm in diameter)
andwas positioned 50 cm above the ﬂoor. Mice were placed in the cen-
ter of the board, and the number of head-dips was counted in a 5 min
period. Decrease in number of head-dips was considered as anxiety-
like behavior in animals. The apparatus was cleaned with 70% ethanol
after testing each mouse.
2.5. Molecular assessments
2.5.1. Glutathione (GSH) measurement
Animals were decapitated under mild anesthesia, and then the hip-
pocampi were dissected on ice-cold surface and immediately immersed
in liquid nitrogen. Sampleswere centrifuged at 3000 g for 10min at 4 °C,
and the supernatant were collected. Glutathione levels were deter-
mined using 5, 50-dithiobis-(2-nitrobenzoic acid) or DTNB as the
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added into 0.1 mol L−1 of phosphate buffer and 0.04% DTNB in a total
volume of 3.0 mL (pH 8.9). The developed color was measured at
412 nm using a spectrophotometer (UV-1601 PC, Shimadzu, Japan).
GSH content was expressed as μg mg−1 protein [39].
2.5.2. ATP assay
ATP levels were measured using luciferase enzyme as described in
our previous work (39). Bioluminescence intensity was measured
using Sirius tube luminometer (Berthold Detection System, Germany).
2.5.3. Measurement of reactive oxygen spices (ROS) formation
2,7-Dichlorodihydroﬂuorescein diacetate was used to measure ROS
production in samples as reported by Vejražka et al. [40]. The sample
was incubated with 5 μM DCF-DA at 30 °C for 15 min in the dark.
Then, ﬂuorescence was read with 485 nm excitation and 520 nm emis-
sion using a ﬂuorimeter. Data were presented per milligram protein of
tissue homogenate.
2.5.4. Nitrite assay
Nitrite measurement was carried out using the method, which was
described in our previous studies. In brief, we measured nitrite levels
as the result of the NO end product and, nitrite levels were determined
using a colorimetric assay based on theGriess reaction. Concentration of
nitrite was determined by reference to a standard curve of sodium ni-
trite (Sigma, USA) and normalized to theweight of each sample [41,42].
2.6. Statistics
Comparison between groups was analyzed using t-test, one-way
and two-way ANOVA followed by Tukey's post hoc test. P b 0.05 wasFig. 1. Effect of different housing conditions, social condition (SC) and isolated condition (IC), on
percentage of time spent in the open arm in the EPM (C), and the percentage of entries in the o
8 animals and were analyzed using t-test. **P b 0.01 and ***P b 0.001 compared with the SC mconsidered statistically signiﬁcant. The factors were housing [social
condition (SC) and isolation condition (IC)] and treatments [control:
no treatment and treatment: drug-administered animals by i.p. injec-
tion] for all assessments.
3. Results
3.1. Effects of housing conditions on anxiety-like behaviors
t-Test analysis revealed that applying SIS to mice in post weaning
state induced anxiety-like behaviors in IC mice when compared to SC
animals. In the OFT, SIS signiﬁcantly decreased the spent time in the
central zone in IC mice when compared to SC mice (P b 0.01, Fig. 1A).
In the HBT, IC mice showed a decrease in number of head-dips in com-
parison with SC animals (P b 0.001, Fig. 1B). In the EPM, percentage of
spent time in the open arms and percentage of open arms entries
were evaluated as variables relevant to anxiety-like behaviors. In com-
parison with SC mice, SIS remarkably decreased percentage of spent
time in the open arms (P b 0.01, Fig. 1C) as well as percentage of open
arms entries (P b 0.001, Fig. 1D) in IC mice.
3.2. Effects of tropisetron on the anxiety-like behaviors in animals
In order to determine the subeffective doses of tropisetron in the
animals, we assessed the effects of various doses of tropisetron (1, 3
and 5 mg/kg, i.p.) on anxiety-like behaviors in both SC and IC mice
using the aforementioned tasks. One-way ANOVA demonstrated that
treatment with all doses of tropisetron produced no signiﬁcant alter-
ations in anxiety-like behaviors in SC mice when compared with
saline-treated SC mice in the OFT (F (4, 25) = 0.2119, P N 0.05, Fig. 2A),
HBT (F (4, 35) = 0.2465, P N 0.05, Fig. 2C), and in the EPM (F (4, 35) =the time spent in the central zone in the OFT (A), number of head-dips in the HBT (B), the
pen arm in the EPM (D) inmalemice. Values are expressed as the mean± S.E.M from 6 to
ice.
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ANOVA analysis revealed that same treatments changed the anxiety-
like behaviors in IC mice in the OFT (F (4, 25) = 8.439, P b 0.001,
Fig. 2B), HBT (F (4, 35) = 6.853, P b 0.001, Fig. 2D), and EPM (F (4, 35) =
4.378, P b 0.01, Fig. 2F) (F (4, 40) = 6.251, P b 0.001, Fig. 2H). In the
OFT, Tukey's analysis showed that administration of tropisetron
(3 and 5 mg/kg, but not 1 mg/kg) to IC mice signiﬁcantly increased
spent time in the central zone in comparison with saline-treated IC
mice (P b 0.05 and P b 0.001). In the HBT, Tukey's analysis showed
that administration of tropisetron (3 and 5 mg/kg, but not 1 mg/kg) to
IC mice signiﬁcantly increased the number of head-dips when com-
pared to saline-treated IC mice (P b 0.05 and P b 0.001). In the EPM,
only treatment with tropisetron 5 mg/kg increased the percentage ofFig. 2. Effect of tropisetron (1, 3, and 5mg/kg) treatment on the time spent in the central zone (
the percentage of entries in the open arm (G, H) in SC and IC animals. Values are expressed as th
Tukey's post hoc test. *P b 0.05, **P b 0.01, and ***P b 0.001 compared with the saline-treated Ispent time in the open arms when compared to saline-treated IC mice
(P b 0.01). In comparison with saline-treated IC mice, treatment with
tropisetron (3 and 5 mg/kg, but not 1 mg/kg) increased the percentage
of open arms entries in IC mice using Tukey's analysis (P b 0.05 and P b
0.01).
3.3. Effects of NO inhibitors/precursor on the anxiety-like behaviors
in animals
In order to determine the effective and subeffective doses of NOS in-
hibitors and NO precursor in the animals, we investigated the effects of
different doses of L-NAME, AG, and L-arg on the anxiety-like behaviors
in both SC and IC mice using the aforementioned tasks. One-wayA, B), number of head-dips (C, D), the percentage of time spent in the open arm (E, F), and
emean± S.E.M from 6 to 9 animals andwere analyzed using one-wayANOVA followed by
C mice (S).
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treated SC animals in the OFT (F (6, 35) = 0.02005, P N 0.05, Fig. 3A),
HBT (F (6, 49) = 0.07436, P N 0.05, Fig. 3C), and in the EPM (F (6, 49) =
0.08503, P N 0.05, Fig. 3E) (F (6, 56) = 0.1118, P N 0.05, Fig. 3G). However,
the results were different in the IC groups; One-way ANOVA showed
that there were signiﬁcant differences between treated IC groups in
the OFT (F (6, 35) = 5.660, P b 0.001, Fig. 3B), HBT (F (6, 49) = 10.07, P b
0.0001, Fig. 3D), and EPM (F (6, 49) = 4.42, P b 0.01, Fig. 3F) (F (6, 56) =
2.971, P b 0.05, Fig. 3H).
Tukey's analyses showed that results obtained from the OFT showed
that administration of L-NAME (10 mg/kg, but not 5 mg/kg) (P b 0.05)
and AG (50 mg/kg, but not 20 mg/kg) (P b 0.01) signiﬁcantly increasedFig. 3. Effects of NO agents including L-NAME 5 and 10 mg/kg, Aminoguanidine (AG) 20 and 1
(A, B), number of head-dips (C, D), the percentage of time spent in the open arm (E, F), and thep
mean± S.E.M from 6 to 9 animals and were analyzed using one-way ANOVA followed by Tuke
mice (S).the time spent in the central zone in the IC mice in comparison
with saline-treated IC mice, while treatment with L-Arg (50 and
100 mg/kg) had no effect on the time spent in the central zone (P N
0.05). In the HBT as shown in Fig. 3D, subeffective doses of L-NAME
(10 mg/kg, but not 5 mg/kg) (P b 0.01) and AG (50 mg/kg, but not
20 mg/kg) (P b 0.001) increased the number of head-dips when com-
pared to saline-treated controls. However, treatment with L-arg
(50 and 100 mg/kg) had no effect on the number of head-dips in the
ICmice (P N 0.05). In comparisonwith saline-treated IC controls, results
from EPM revealed that applying L-NAME (10 mg/kg, but not 5 mg/kg)
(P b 0.05) and AG (50mg/kg, but not 20mg/kg) (P b 0.01) increased the
percentage of time spent in the open arms, while administration of00 mg/kg, and L-arginine (L-arg) 50 and 100 mg/kg on the time spent in the central zone
ercentage of entries in the open arm (G,H) in SCand IC animals. Values are expressed as the
y's post hoc test. *P b 0.05, **P b 0.01, and ***P b 0.001 compared with the saline-treated IC
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rameters (P N 0.05). In addition, same as the last parts, treatment with
L-NAME (10 mg/kg, but not 5 mg/kg) (P b 0.05) and AG (50 mg/kg,
but not 20 mg/kg) (P b 0.05) showed signiﬁcant changes in the
percentage of entries in the open arms of EPM in IC animals when
compared with saline treated IC mice. Administration of L-arg (50 and
100mg/kg) produced no signiﬁcant change in the percentage of entries
in the open arms of EPM in IC animals (P N 0.05). In comparison to
saline-treated SC mice, Tukey's analyses showed that administration
of the same doses of above drugs had no effect on the anxiety-like be-
haviors of SCmice in theOFT, HBT, and in the EPM(P N 0.05). It is impor-
tant to note that AG is a relatively speciﬁc inhibitor of iNOS and at
higher concentrations; it may still suppress constitutive NOS. Thus,
dosages of AG (20 and 50 mg/kg) were selected based on the previous
studies that reported these dosages have no effect on constitutive NOS
[43,44].Fig. 4. Effect of L-NAME pretreatment (5 mg/kg) on the tropisetron-treated animals (1 mg/kg
tropisetron-treated animals (1mg/kg) in SC and IC animals (C, D) and, Effect of pre-treatmentw
Animals were tested using OFT and time spent in the central zonewas evaluated. Values are exp
compared with vehicle-treated group. ##P b 0.01 compared with tropisetron (5 mg/kg)-treate3.4. Effects of nitrergic system on anxiolytic properties of tropisetron
3.4.1. Anxiety-like behaviors in the OFT
Two-way ANOVA analysis revealed that co-administration of
subeffective doses of NOS inhibitors/NO precursor with subeffective
dose of tropisetron had no effect on the spent time in the central zone
in comparison to saline-treated SC mice (P N 0.05, Fig. 4A, C, E).
On the other hand, co-administration of L-NAME (5 mg/kg)along
with tropisetron (1 mg/kg) increased the spent time in the central
zone in IC animals when compared to saline-treated IC controls
(P b 0.05, Fig, 4B). A two way ANOVA revealed signiﬁcant differences
in the OFT for the tropisetron treatment (F (1, 20) = 11.08, P b 0.01),
L-NAME treatment (F (1, 20) = 5.610, P b 0.05), and their interaction
(F (1, 20) = 4.365, P b 0.05).
Also, injecting a subeffective dose of AG (20 mg/kg) to tropisetron-
treated IC animals (1 mg/kg) caused an obvious anxiolytic effect when) in SC and IC animals (A, B), Effect of pretreatment with AG (20 mg/kg) on subeffective
ith L-arg (50mg/kg) on tropisetron-treated animals (5mg/kg) (E, F) in SC and IC animals.
ressed as themean± S.E.M. (n= 6–9) using two-way ANOVA. **P b 0.01 and ***P b 0.001
d group.
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ANOVA revealed signiﬁcant differences for the tropisetron treatment
(F (1, 20) = 13.11, P b 0.01), AG treatment (F (1, 20) = 7.479, P b 0.05),
and their interaction (F (1, 20) = 5.253, P b 0.05).
In addition, treatmentwith L-arg (50mg/kg) abolished the anxiolyt-
ic effect of tropisetron 5mg/kg via decreasing the spent time in the cen-
tral zone when compared to IC saline group (P b 0.01, Fig. 4F). A two
way ANOVA revealed signiﬁcant differences for the tropisetron treat-
ment (F (1, 20) = 25.04, P b 0.0001), L-arg treatment (F (1, 20) = 7.345,
P b 0.05), and tropisetron × L-arg (F (1, 20) = 7.150, P b 0.05).
3.4.2. Anxiety-like behaviors in the HBT
Co-administration of L-NAME (5mg/kg) with tropisetron (1mg/kg)
increased the number of head-dips in the IC animals in comparisonwith
saline-treated IC mice (P b 0.05, Fig. 5B). A two way ANOVA revealedFig. 5. Effect of L-NAME pretreatment (5 mg/kg) on the tropisetron-treated animals (1 mg/kg
tropisetron-treated animals (1mg/kg) in SC and IC animals (C, D) and, Effect of pre-treatmentw
Animalswere tested usingHBT and number of head-dipswasmeasured. Values are expressed a
with vehicle-treated group. #P b 0.05 compared with tropisetron (5 mg/kg)-treated group.signiﬁcant differences in the HBT for the tropisetron treatment
(F (1, 28) = 4.233, P b 0.05) and L-NAME treatment (F (1, 28) = 8.003,
P b 0.01), but not their interaction (F (1, 28) = 0.8892, P b 0.05).
On the other hand, combination of the subeffective doses of the
tropisetron with AG (20 mg/kg) signiﬁcantly affected the number of
head-dips of IC mice (P b 0.05, Fig. 5D) and in two-way ANOVA we ob-
served signiﬁcant differences between tropisetron treatment (F (1, 28)=
10.36, P b 0.01), AG treatment (F (1, 28) = 23.30, P b 0.0001), and
tropisetron × AG (F (1, 28) = 5.506, P b 0.05).
In comparison with saline-treated IC mice, co-administration of
L-arg (50 mg/kg) with tropisetron (5 mg/kg) impaired the anxiolytic-
like effect of tropisetron by decreasing the number of head-dips
(P b 0.05, Fig. 5D). Also, twoway ANOVA showed signiﬁcant differences
for the tropisetron treatment (F (1, 28) = 9.925, P b 0.01), L-arg treat-
ment (F (1, 28) = 4.311, P b 0.05), and tropisetron × L-arg treatment) in SC and IC animals (A, B), Effect of pretreatment with AG (20 mg/kg) on subeffective
ith L-arg (50mg/kg) on tropisetron-treated animals (5mg/kg) (E, F) in SC and IC animals.
s themean± S.E.M. (n=6–9) using two-wayANOVA. *P b 0.05 and***P b 0.001 compared
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administration of the same doses of above drug combinations had no
effect on the anxiety-like behaviors of SC mice in HBT (P N 0.05,
Fig. 5A, C, E).
3.4.3. Anxiety-like behaviors in the EPM
In comparison to saline-treated controls, treatment the ICmice with
combination of tropisetron (1 mg/kg) and L-NAME (5 mg/kg) signiﬁ-
cantly increased the percentage of time spent in the open arms
(P b 0.05, Fig. 6B) as well as percentage of open arms entries (P b 0.01,
Fig. 7B). Also, two way ANOVA analysis demonstrated signiﬁcant
differences in the percentage of time spent in the open arms and open
arms entries for the tropisetron treatment (F (1, 28) = 5.628, P b 0.05;
F (1, 32) = 4.235, P b 0.05) and L-NAME treatment (F (1, 28) = 5.287,
P b 0.05; F (1, 32)= 10.32, P b 0.01), but not tropisetron × L-NAME treat-
ment (F (1, 28) = 0.2997, P N 0.05; F (1, 32) = 3.943, P N 0.05).Fig. 6. Effect of L-NAME pretreatment (5 mg/kg) on the tropisetron-treated animals (1 mg/kg
tropisetron-treated animals (1mg/kg) in SC and IC animals (C, D) and, Effect of pre-treatmentw
Animals were tested using EPM and the percentage of time spent in the open armwasmeasure
and **P b 0.01 compared with vehicle-treated group. ##P b 0.01 compared with tropisetron (5In addition, co-administration of tropisetron (1 mg/kg) with AG
(20 mg/kg) induced a signiﬁcant increase in the percentage of time
spent in the open arms (P b 0.01, Fig. 6D) as well as percentage of
open arms entries (P b 0.001, Fig. 7D) as compared to saline-treated IC
mice. A two way ANOVA showed mostly signiﬁcant differences in the
percentage of time spent in the open arms and open arms entries for
the tropisetron treatment (F (1, 28) = 7.152, P b 0.01; F (1, 32) = 5.378,
P b 0.05), AG treatment (F (1, 28) = 9.276, P b 0.05; F (1, 32) = 20.86,
P b 0.0001), and tropisetron × AG treatment (F (1, 28) = 0.6677,
P N 0.05; F (1, 32) = 5.057, P b 0.05).
Also, comparison with saline-treated IC controls showed that ad-
ministration of L-arg (50 mg/kg) abolished the anxiolytic-like effects
of tropisetron (5 mg/kg) by reducing the percentage of spent time in
the open arms (P b 0.01, Fig. 6F) as well as percentage of open arms
entries(P b 0.001, Fig. 7F). TwowayANOVA analysis revealed signiﬁcant
differences in the percentage of time spent in the open arms and open) in SC and IC animals (A, B), Effect of pretreatment with AG (20 mg/kg) on subeffective
ith L-arg (50mg/kg) on tropisetron-treated animals (5mg/kg) (E, F) in SC and IC animals.
d. Values are expressed as the mean± S.E.M. (n= 6–9) using two-way ANOVA. *P b 0.05
mg/kg)-treated group.
Fig. 7. Effect of L-NAME pretreatment (5 mg/kg) on the tropisetron-treated animals (1 mg/kg) in SC and IC animals (A, B), Effect of pretreatment with AG (20 mg/kg) on subeffective
tropisetron-treated animals (1mg/kg) in SC and IC animals (C, D) and, Effect of pre-treatmentwith L-arg (50mg/kg) on tropisetron-treated animals (5mg/kg) (E, F) in SC and IC animals.
Animals were tested using EPM and the percentage of entries in the open armwasmeasured. Values are expressed as themean± S.E.M. (n= 6–9) using two-way ANOVA. **P b 0.01 and
***P b 0.001 compared with vehicle-treated group. ###P b 0.001 compared with tropisetron (5 mg/kg)-treated group.
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F (1, 32) = 4.504, P b 0.05), L-arg treatment (F (1, 28) = 4.266, P b 0.05;
F (1, 32) = 7.594, P b 0.01), and tropisetron × L-arg treatment (F (1, 28) =
9.857, P b 0.01; F (1, 32) = 11.49, P b 0.01). In comparison to saline-
treated SC mice, administration of the same doses of above drug
combinations had no effect on the anxiety-like behaviors of SC mice in
any of behavioral assessments in the EPM (P N 0.05, Fig. 6A, C, E and
Fig. 7A, C, E).
3.5. Effects of different housing conditions and drug treatments on
mitochondrial function and O&NS
3.5.1. Effects of housing conditions and drug treatments onGSH levels in the
hippocampus
Table 1 shows a signiﬁcant decrease in GSH levels of hippocampal
cytosolic fraction of IC mice in comparison with SC animals usingTukey's analysis (P b 0.01). Administration of tropisetron (5 mg/kg)
signiﬁcantly restored GSH levels in comparison with saline-treated IC
mice (P b 0.001). However, However, Tukey's analysis showed that
treatment with tropisetron 1 mg/kg failed to induce any signiﬁcant
change in GSH levels when compared to saline-treated IC mice (P N
0.05). Similarly, administration of subeffective doses of L-NAME
(5 mg/kg), AG (20mg/kg), and L-arg (50 and 100mg/kg) had no signif-
icant change on the hippocampal GSH levels in IC mice as compared to
saline controls (P N 0.05). However, higher doses of L-NAME (10mg/kg)
(P b 0.05) and AG (50 mg/kg) (P b 0.01) signiﬁcantly affect the hippo-
campal GSH levels in IC animals. In comparison with saline treated IC
mice, treating IC mice with AG 20 mg/kg (but not L-NAME 5 mg/kg)
in combination with tropisetron (1 mg/kg) signiﬁcantly restored GSH
levels (P b 0.001). In addition, administration of L-arg (50mg/kg) signif-
icantly lowered the elevated levels of GSH in IC mice treated with
tropisetron 5 mg/kg (P b 0.001).
Table 1
Effect of different housing conditions and treatments on glutathione (GSH), ATP, and nitrite level in hippocampus.
Groups GSH
(μg/mg protein)
ATP
(nmol/mg protein)
Nitrite
(nmol/mg protein)
Social condition (SC) 14.7 ± 2.3 3.1 ± 0.1 81 ± 5
Isolated condition (IC) 7.1 ± 0.8** 1.9 ± 0.1** 143 ± 6***
+Tropisetron (1 mg/kg) 8.1 ± 0.8** 1.9 ± 0.3** 133 ± 5***
+Tropisetron (5 mg/kg) 14.7 ± 2.6 ### 3 ± 0.5### 93 ± 5##
+L-NAME (5 mg/kg) 7.6 ± 1.1** 1.8 ± 0.4** 137 ± 6***
+L-NAME (10 mg/kg) 9.8 ± 0.6# 2.6 ± 0.3# 112 ± 3#
+Aminoguanidine (20 mg/kg) 7.8 ± 1** 1.9 ± 0.2** 135 ± 8***
+Aminoguanidine (50 mg/kg) 11.6 ± 1.2## 3 ± 0.6## 120 ± 5**
+L-arginine (50 mg/kg) 7 ± 1.3** 1.8 ± 0.3** 147 ± 9***
+ L-arginine (100 mg/kg) 6.8 ± 0.9** 1.9 ± 0.4** 157 ± 11***
+Tropisetron (1 mg/kg) + L-NAME (5 mg/kg) 7.6 ± 1.6** 2.4 ± 0.1 # 109 ± 8#
+Tropisetron (1 mg/kg) + Aminoguanidine (20 mg/kg) 11.3 ± 2.5### 3.1 ± 0.3 ### 78 ± 6###
+Tropisetron (5 mg/kg) + L-Arginine (50 mg/kg) 7.4 ± 1.3*** 1.8 ± 0.2** 129 ± 7***
Reduced GSH levels were determined according to the method of Riener et al. (2002) using Ellman's reagent (5,5′-dithiobis-(2-nitrobenzoic acid, DTNB) as described in Materials and
methods.ATP level were determined using Luciferin/Luciferase Enzyme System as described in Materials and methods. Nitrite level was evaluated based on our previously described
method. Values represented asmean± S.E.M. (n=3–6). *P b 0.05, **P b 0.01, and ***P b 0.001 comparedwith SC group and#P b 0.05; ##P b 0.01; ###P b 0.001 comparedwith IC group.
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hippocampus
Results obtained fromTukey's analysis revealed that there is a signif-
icant decrease in ATP production in the hippocampus of ICmice as com-
pared with SC controls (P b 0.01). Also, administration of subeffective
doses of AG (20 mg/kg), L-NAME (5 mg/kg), L-arg (50 and 100 mg/kg),
and tropisetron (1mg/kg) did not restore ATP levels in the hippocampus
of IC animals when compared to saline-treated IC mice (P N 0.05).
Tukey's analysis demonstrated that treatment of IC mice with
tropisetron (5 mg/kg) increased ATP levels in the hippocampus
in comparison with saline-treated IC mice (P b 0.001). Furthermore,
co-administration of subeffective dose of L-arg (50 mg/kg) abolished
the effect of tropisetron on ATP generation (P b 0.01). On the other
hand, co-administration of L-NAME (5 mg/kg) or AG (20 mg/kg) with
tropisetron (1 mg/kg) signiﬁcantly increased ATP levels in the
hippocampus of IC mice in comparison with IC controls (P b 0.05 and
P b 0.001 respectively).Table 2
% Increased of ROS formation in hippocampus after treatment with different drugs in
social and isolated condition.
Groups DCF ﬂuorescence intensity (%)
5 min 45 min
Social condition (SC) 2 ± 1 8 ± 3
Isolated condition (IC) 15 ± 3** 187 ± 16***
+Tropisetron (1 mg/kg) 21 ± 1*** 147 ± 5***
+Tropisetron (5 mg/kg) 4 ± 2### 38 ± 3 ###
+L-NAME (5 mg/kg) 16 ± 5*** 163 ± 21***
+L-NAME (10 mg/kg) 9 ± 2# 79 ± 16##
+Aminoguanidine (20 mg/kg) 14 ± 3** 151 ± 19***
+Aminoguanidine (50 mg/kg) 6 ± 2### 45 ± 13###
+L-arginine (50 mg/kg) 16 ± 4** 184 ± 21***
+ L-arginine (100 mg/kg) 17 ± 3** 199 ± 23***
+Tropisetron (1 mg/kg) + L-NAME (5 mg/kg) 9 ± 2## 37 ± 9###
+Tropisetron (1 mg/kg) + aminoguanidine
(20 mg/kg)
5 ± 1### 15 ± 2 ###
+Tropisetron (5 mg/kg) + L-arginine (50 mg/kg) 11 ± 2* 21 ± 4***
ROS generation measured by DCF formation method expressed as ﬂuorescent intensity
units as described in Materials and methods and demonstrated as ﬂuorescence intensity
of DCF. Values represented as mean ± S.E.M. (n = 3–6). Social condition (SC; Control)
group contains respiration buffer plus DCFH-DA (10 μM). *P b 0.05; **P b 0.01; ***P b
0.001 compared with SC group and #P b 0.05; ##P b 0.01; ###P b 0.001 compared with
IC group at the same time interval. Fluorescence intensity (%) is described as the percent-
age of ﬂuorescence intensity compared with social condition (SC) groups.3.5.3. Effects of housing conditions and drug treatments on nitrite levels in
the hippocampus
Tukey's analysis revealed that IC mice have greater levels of nitrite
content in comparison with SC animals (P b 0.001). Also, there was no
signiﬁcant difference in the hippocampal nitrite levels between saline-
treated IC mice and IC mice treated with subeffective doses of AG
(20 and 50 mg/kg), L-NAME (5 mg/kg), L-arg (50 and 100 mg/kg),
and tropisetron (1 mg/kg) (P N 0.05). In comparison with saline-
treated IC mice, a signiﬁcant decrease in hippocampal nitrite levels
was observed, when IC mice were treated with tropisetron (5 mg/kg)
(P b 0.01). Also, co-administration of subeffective doses of L-arg
(50 mg/kg) blocked the effect of tropisetron on nitrite reduction (P b
0.001). Furthermore, co-administration of L-NAME (5 mg/kg) or
AG (20 mg/kg)with tropisetron (1mg/kg) signiﬁcantly decreased the ni-
trite levels in the hippocampus of IC mice in comparison with IC controls
(P b 0.05 and P b 0.001 respectively) (Table 2).
3.5.4. Effects of housing conditions and drug treatments on ROS formation
in the hippocampus
Assessment of ROS formation performed in 2 time intervals (5 min
and 45 min) as described above. A sizable increase in hippocampal
ROS generation was observed in IC mice at both 5 and 45 min intervals
when compared to SC controls using tukey's analysis (P b 0.01 and
P b 0.001 respectively). Treating IC mice with AG (20 mg/kg), L-NAME
(5 mg/kg), L-arg (50 and 100 mg/kg), and tropisetron (1 mg/kg) did
not affect the elevated levels of ROS formation in the hippocampus
when compared with saline-treated IC animals (P N 0.05). Also, in
comparison with IC controls, administration of tropisetron (5 mg/kg)
to IC animals reversed the hippocampal ROS levels to normal state
(P b 0.001), and the effect was blocked by administration of L-arg
(50 mg/kg) (P b 0.05 and P b 0.001). Moreover, co-administration of
L-NAME (5 mg/kg) or AG (20 mg/kg) with tropisetron (1 mg/kg) de-
creased the enhanced ROS production in the hippocampus of IC animals
as compared to IC controls at both 5 min (P b 0.01 and P b 0.001 respec-
tively) and 45 min (P b 0.001 and P b 0.001 respectively) intervals
(Table 2).
4. Discussion
Results of the current study revealed that experiencing early SIS dur-
ing developmental stages of brain in the adolescence produces anxiety-
like behaviors and impairsmitochondrial activity in the hippocampus of
animals. Our results also provided preliminary evidence that tropisetron
exerts anxiolytic effect via modulating the NO, which per se mediates
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drial challenge.
Applying animal models of chronic stress provide conditions to in-
vestigate underlying mechanisms of stress-related behaviors similar to
anxiety disorders in humans [31]. Previous studies have reported that
SIS is a cogent psychosocial stress, which capable of inducing emotional
changes as well as enduring and permanent anxious state in rodents
[45]. In the current study, we evaluated the anxiety-like responses of
adult mice using behavioral tests, which were approved as valid para-
digms to assess anxiety-like behaviors including EPM,OFT, andHBT. Ap-
plying SIS to adolescent mice induced signiﬁcant anxiogenic effects,
which reversed by administration of subeffective doses of tropisetron,
L-NAME, and AG. Also, co-administration of subeffective doses of
AG-tropisetron and L-NAME-tropisetron produced the same effects.
However, these treatments had no effect on SC mice. Stress induces a
variety of neurochemical changes in the brain that leads to elevation
of excitatory amino acids such as glutamate, which causes an overpro-
duction of NO in the brain [46,47]. Increased expression of NOS isoforms
or elevated levels of NOmetabolites was reported in the limbic areas in
various studies using SIS paradigm [48,49]. Also, participation of NO in
anxiety-like behaviors after stressful conditions is well documented in
the literature. Similar to our results, there are studies reported that
administration of L-NAME and AG exhibited anxiolytic properties in
rodents [17,50,51].
Evidence indicated that early SIS disrupts the maturation of neuro-
transmission systems such as serotonergic system that regulates
anxiety-like behaviors. Alterations in the serotonergic system following
early SIS have been reported in different regions of the brain including
limbic area [6]. Limbic system is considered to be involved in the
anxiety-like behaviors and has a rich content of 5-HT3 receptors.
These receptors strongly contribute to maturation of inhibitory net-
works that moderate the excitatory neurotransmission. Also, 5-HT3 re-
ceptors are implicated in pathophysiology of the several developmental
disorders including affective disorders [23]. Our results were consistent
with previous studies that reported 5-HT3 receptor antagonists, in addi-
tion to their anxiolytic properties, are able to decrease the NO levels as
well as iNOS expression in the brain under pathologic conditions [52].
Therefore, protective effect of tropisetron against O&NS as well as be-
havioral alterations in IC mice may be related to modulate the nitrergic
system (mainly iNOS) in the brain. In this context, our results revealed
that anxiolytic effects of tropisetron in the EPM(increase the percentage
of entries and spent time in the open arms), OFT (increase in the spent
time in central zone) and HBT (increase in number of head-dips) are
mediated partly by nitrergic system. To support this, we measured the
levels of ROS generation, GSH, nitrite andATP in the hippocampus of ex-
perimental groups. Results showed that SIS negatively upsets mito-
chondrial function by massive production of ROS and nitrite as well as
a signiﬁcant decrease in ATP and GSH levels. Ample evidence indicates
that developing brain is speciﬁcally susceptible to O&NS–mediated
damage because of a high contents of unsaturated fatty acids, low levels
of antioxidant capacity and also high rate of oxygen consumption [53].
Our ﬁndings showed that co-administration of subeffective doses of
tropisetron and NOS inhibitors (L-NAME, AG) or treatment with
tropisetron alone effectively succeeded to reverse the elevated levels
of ROS and nitrite aswell as GSH and ATP depletion in the hippocampus
of IC mice. In this respect, best results were observed with co-
administration of the tropisetron and AG, which potently improved
the oxidative challenge in IC mice. It is important to note that unlike
IC mice, same treatments had no effect on the hippocampal nitrite,
ATP, ROS and GSH levels in SC mice. Additionally, L-arg as a NO precur-
sor blocked the protective effects of latter treatments against SIS-
induced O&NS in IC and not SC mice. Accumulating evidence suggests
that oxidative stress and antioxidant imbalance contribute to pathogen-
esis of mood and anxiety disorders [8–10]. Evidence reported that psy-
chosocial stressors cause impairments in the oxidant/antioxidant
equilibrium through boosting the generation of ROS and NO in thespeciﬁc brain regions such as hippocampus [54]. Also, previous research
has shown that psychosocial stressors decrease GSH levels in the brain
which is accompanied by reduced activity of antioxidant enzymes and
mitochondrial dysfunction [15,55]. Based on our results, SIS-induced
changes in mitochondrial function and O&NS were accompanied by
anxiety-like behaviors in IC mice. In this case, Filiou et al. revealed that
the mouse model of high anxiety-related behavior has mitochondrial
dysfunction in the brain. They also showed that mitochondrial dysfunc-
tion plays a part in neurotransmission disequilibrium which has been
considered as the hallmark of anxiety disorders [7,56]. In addition, ﬁnd-
ings of other laboratories corroborated the involvement ofmitochondri-
al dysfunction in etiology of psychiatric disorders including depression
[57,58]. Also, clinical studies revealed that mood disorders are of most
prevalent symptoms observed in children and adolescents with mito-
chondrial disorders [59,60]. In conclusion, results of this study showed
that anxiogenic effect of early SIS was partly mediated by NO-induced
O&NS along with impaired mitochondrial function. Also, our ﬁndings
revealed that nitrergic system plays a role in anxiolytic properties
of tropisetron in IC mice via reversing the negative impact of SIS on
mitochondrial performance.References
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